Download Cancer Immunotherapy at the Crossroads: How Tumors Evade by James H. Finke (Editor), Ronald M. Bukowski (Editor) PDF

By James H. Finke (Editor), Ronald M. Bukowski (Editor)

Major investigators and clinicians aspect different mechanisms utilized by tumors to flee and impair the immune approach after which spell out attainable medical thoughts to avoid or opposite tumor-induced immune disorder. The authors evaluation the mechanisms of immune disorder and evasion mechanisms in histologically assorted human tumors, targeting tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), that can function biomarkers for sufferer diagnosis. They talk about the potential wherein those immune services should be safe or restored with a purpose to extra successfully help the method of tumor rejection in situ. state-of-the-art recommendations are defined with the means to observe the energy and caliber of sufferers' immune responses utilizing immunocytometry, MHC-peptide tetramers mixed with apoptosis assay, ELISPOT assay, and detection of MHC-TAA peptide complexes on tumor cells.

Show description

Read Online or Download Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology) PDF

Best cancer books

Palliative Care Consultations in Advanced Breast Cancer (Palliative Care Consultations)

The Palliative Care Consultations sequence is basically aimed toward these participants operating in an acute medical institution melanoma heart and/or tertiary referral heart. Books are designed to provide the busy clinician recommendation on scientific difficulties, either these not often encountered and those who are quite common, yet tricky.

Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)

Prime investigators and clinicians aspect the various mechanisms utilized by tumors to flee and impair the immune process after which spell out attainable scientific suggestions to avoid or opposite tumor-induced immune disorder. The authors evaluation the mechanisms of immune disorder and evasion mechanisms in histologically assorted human tumors, targeting tumor-induced molecular defects in T cells and antigen-presenting cells (dendritic cells and tumors), which could function biomarkers for sufferer analysis.

Etiology of Cancer in Man

This quantity experiences our present wisdom bearing on can­ a number of chapters speak about the contributions of genetic asp­ cer progress and development because it pertains to the etiology of ects, metabolism, endocrine-related points and foodstuff to human melanoma. As emphasised in Volumes I-V of this sequence, melanoma development.

Breast Cancer: Methods and Protocols

This quantity presents assets, principles, and bench manuals for the learn of breast melanoma. This publication is split into 5 sections: equipment utilized in scientific laboratory for analysis (Detection of Molecular Markers of Breast Cancer); tools utilized in either medical and examine laboratories for trying out genetic changes (Genetic Detection of Breast melanoma) and (Isolation of Breast melanoma Cells); tools used to check the habit of breast melanoma cells (In Vitro Experimental Assays for Breast Cancer); and strategies used for mimicking human breast melanoma in a residing organism (In Vivo Experimental types for Breast Cancer).

Extra info for Cancer Immunotherapy at the Crossroads: How Tumors Evade Immunity and What Can Be Done (Current Clinical Oncology)

Sample text

Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, et al. FN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism. J Clin Investig 2002;110:1515–1523. 23. Hicklin DJ, Marincola FM, Ferrone S. HLA class I antigen downregulation in human cancers: T-cell immunotherapy revives an old story. Mol Med Today 1999;5:178–186. 24. Fukusato T, Gerber MA, Thung SN, Ferrone S, Schaffner F. Expression of HLA class I antigens on hepatocytes in liver disease.

32 Part I / Basic Mechanisms of Immune Evasion 71. Seliger B, Ritz U, Abele R, Bock M, Tampe R, Sutter G, et al. Immune escape of melanoma: first evidence of structural alterations in two distinct components of the MHC class I antigen processing pathway. Cancer Res 2001;61:8647–8650. 72. Corrias MV, Occhino M, Croce M, De Ambrosis A, Pistillo MP, Bocca P, et al. Lack of HLAclass I antigens in human neuroblastoma cells: analysis of its relationship to TAP and tapasin expression. Tissue Antigens 2001;57:110–117.

Nat Immunol 2002;3:611–618. 11. Toso JF, Gill VJ, Hwu P, Marincola FM, Restifo NP, Schwartzentruber DJ, et al. Phase I study of the intravenous administration of attenuated Salmonella typhimurium to patients with metastatic melanoma. J Clin Oncol 2002;20:142–152. 12. Parmiani G, Castelli C, Dalerba P, Mortarini R, Rivoltini L, Marincola FM, et al. Cancer immunotherapy with peptide-based vaccines: what have we achieved? Where are we going? J Natl Cancer Inst 2002;94:805–818. 13. Marchand M, Weynants P, Rankin E, Arienti F, Belli F, Parmiani G, et al.

Download PDF sample

Rated 4.10 of 5 – based on 46 votes